Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMBHPDW)

• Drug Name: Phenylbutyrate Drug Info
• Synonyms: Benzenebutyric acid; Phenyl butanoate; Phenyl butyrate; HDInhib_000004; Butanoic acid, phenyl ester; Butyric acid, phenyl ester; FR-2080; Gamma-Phenylbutyric acid; Omega-Phenylbutanoic acid; GAMMA-PHENYL-BUTYRIC ACID; Butyric acid, 4-phenyl-(8CI); 1-Phenylbutyric acid; 4-PHENYL-BUTANOIC ACID; 4-PHENYLBUTYRIC ACID; 4-Phenylbutanoic acid; 4-phenylbutans; 4-phenylbutyrate

Indication

Disease Entry	ICD 11	Status	REF
Urea cycle disorder	5C50.A	Phase 2	[1] , [2]

• Cross-matching ID:
  PubChem CID: 4775
  ChEBI ID: CHEBI:41500
  CAS Number: CAS 1821-12-1
  TTD Drug ID: DMBHPDW

Molecule-Related Drug Atlas

Drug(s) Targeting Sodium channel unspecific (NaC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[3]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[4]
Zonisamide	DM0DTF7	Epilepsy	8A60-8A68	Approved	[5]
Eslicarbazepine	DMZREFQ	Seizure disorder	8A6Z	Approved	[6]
Lidoflazine	DMV23GL	Angina pectoris	BA40	Approved	[7]
Lomerizine	DME0TC8	Migraine	8A80	Approved	[8]
Levobupivacaine	DM783CH	Anaesthesia	9A78.6	Approved	[9]
Tetrodotoxin	DMWMPRG	Bacterial infection	1A00-1C4Z	Approved	[10]
Permethrin	DMZ0Q1G	Sarcoptes scabiei infection	1G04	Approved	[11]
Rufinamide	DMWE60C	Epilepsy	8A60-8A68	Approved	[12]

Drug(s) Targeting Gamma-aminobutyric acid receptor (GAR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Phenobarbital	DMXZOCG	Seizure disorder	8A6Z	Approved	[13]
Allopregnanolone	DMNLHAC	Depression	6A70-6A7Z	Approved	[14]
THIOCOLCHICOSIDE	DMEPWYA	Muscle spasm	MB47.3	Approved	[15]
Clonazepam	DMTO13J	Epilepsy	8A60-8A68	Approved	[16]
Piperazine	DMTY9LU	Ascariasis	1F62	Approved	[17]
Alpidem	DMN7Y9K	Anxiety disorder	6B00-6B0Z	Approved	[18]
Moxidectin	DMYGHX5	Onchocerciasis	1F6A	Approved	[19]
DP-VPA	DMGOXPQ	Bipolar disorder	6A60	Approved	[20]
Androsterone	DMITJAK	N. A.	N. A.	Phase 3	[14]
ZK-93423	DMFWMKZ	Epileptic seizures	8A61-8A6Z	Phase 3	[21]

Drug(s) Targeting Histone deacetylase 1 (HDAC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Vorinostat	DMWMPD4	Cutaneous T-cell lymphoma	2B01	Approved	[22]
Romidepsin	DMT5GNL	Cutaneous T-cell lymphoma	2B01	Approved	[23]
Panobinostat	DM58WKG	Multiple myeloma	2A83	Approved	[22]
HBI-8000	DMDWYUN	Non-small-cell lung cancer	2C25.Y	Registered	[24]
ITF2357	DMFZBNE	Duchenne dystrophy	8C70	Phase 3	[25]
NVP-LAQ824	DM8JWNA	Mood disorder	6A60-6E23	Phase 3	[26]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[27]
MGCD-0103	DM726HX	Non-small-cell lung cancer	2C25.Y	Phase 2	[22]
Resminostat	DMNE1FR	Hepatocellular carcinoma	2C12.02	Phase 2	[28]
Sodium butyrate	DMKNIVG	Acute myeloid leukaemia	2A60	Phase 2	[29]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Gamma-aminobutyric acid receptor (GAR)	TTNJYV2	NOUNIPROTAC	Agonist	[2]
Histone deacetylase 1 (HDAC1)	TT6R7JZ	HDAC1_HUMAN	Inhibitor	[2]
Sodium channel unspecific (NaC)	TTRK8B9	NOUNIPROTAC	Blocker	[2]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8480).
• [2] Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
• [3] Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs. 2009;23(7):555-68.
• [4] Sidedness of carbamazepine accessibility to voltage-gated sodium channels. Mol Pharmacol. 2014 Feb;85(2):381-7.
• [5] Antiepileptic drugs and relapse after epilepsy surgery. Epileptic Disord. 2008 Sep;10(3):193-8.
• [6] Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43.
• [7] Synthesis and pharmacological evaluation of phenylacetamides as sodium-channel blockers. J Med Chem. 1994 Jan 21;37(2):268-74.
• [8] Medicinal chemistry of neuronal voltage-gated sodium channel blockers. J Med Chem. 2001 Jan 18;44(2):115-37.
• [9] Block of neuronal tetrodotoxin-resistant Na+ currents by stereoisomers of piperidine local anesthetics. Anesth Analg. 2000 Dec;91(6):1499-505.
• [10] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [11] In vitro assays for repellents and deterrents for ticks: differing effects of products when tested with attractant or arrestment stimuli. Med Vet Entomol. 2003 Dec;17(4):370-8.
• [12] Emerging drugs for epilepsy. Expert Opin Emerg Drugs. 2007 Sep;12(3):407-22.
• [13] DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
• [14] Neurosteroid analogues. 11. Alternative ring system scaffolds: gamma-aminobutyric acid receptor modulation and anesthetic actions of benz[f]indenes. J Med Chem. 2006 Jul 27;49(15):4595-605.
• [15] 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
• [16] Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
• [17] Cyclooctadepsipeptides--an anthelmintically active class of compounds exhibiting a novel mode of action. Int J Antimicrob Agents. 2003 Sep;22(3):318-31.
• [18] Synthesis and binding affinity of 2-phenylimidazo[1,2-alpha]pyridine derivatives for both central and peripheral benzodiazepine receptors. A new se... J Med Chem. 1997 Sep 12;40(19):3109-18.
• [19] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [20] DP-VPA D-Pharm. Curr Opin Investig Drugs. 2002 Jun;3(6):921-3.
• [21] Structural requirements for agonist actions at the benzodiazepine receptor: studies with analogues of 6-(benzyloxy)-4-(methoxymethyl)-beta-carbolin... J Med Chem. 1990 Mar;33(3):1062-9.
• [22] Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov. 2009 Sep;8(9):724-32.
• [23] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [24] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [25] Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs. 2009 Sep;14(3):471-9.
• [26] NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood. 2003 Oct 1;102(7):2615-22.
• [27] Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
• [28] 2011 Pipeline of 4SC AG.
• [29] Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006 Sep;5(9):769-84.